Basilea Pharmaceutica AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 2000-01-01

Employees: 147

Market Cap: $676.7M

Website: http://www.basilea.com

Clinical Trials

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

Conditions: Invasive Fungal Infections

First Posted Date: 2024-05-29

Last Posted Date: 2024-05-29

Lead Sponsor: Basilea Pharmaceutica

Registration Number: NCT06433128

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Phase 3

Completed

Conditions: Neonatal Sepsis

Interventions: Drug: Ceftobiprole medocaril

First Posted Date: 2023-05-12

Last Posted Date: 2024-12-20

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 9

Registration Number: NCT05856227

Locations: 🇵🇱
Szpital Uniwersytecki - Klinika Neonatologii, Wroclaw, Poland
🇸🇰
Univerzitna nemocnica Martin, Martin, Slovakia
🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

and more 11 locations

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.

Phase 1

Recruiting

Conditions: Hepatic Impairment

Interventions: Drug: Fosmanogepix

First Posted Date: 2022-10-17

Last Posted Date: 2024-12-12

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 24

Registration Number: NCT05582187

Locations: 🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States

A Bioequivalence Study of APX001 High-load and Low-load Tablets

Phase 1

Completed

Conditions: Invasive Fungal Infections

Interventions: Drug: APX001
Drug: APX001A

First Posted Date: 2022-08-08

Last Posted Date: 2024-07-11

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 18

Registration Number: NCT05491733

Locations: 🇺🇸
Pharmaceuticals Research Associates, Inc, Salt Lake City, Utah, United States

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Phase 3

Recruiting

Conditions: Candidemia
Candidiasis, Invasive

Interventions: Drug: Fosmanogepix
Drug: Caspofungin
Drug: Placebo
Drug: Fluconazole

First Posted Date: 2022-06-16

Last Posted Date: 2024-12-19

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 450

Registration Number: NCT05421858

Locations: 🇺🇸
Washington University School of Medicine, Infectious Diseases Clinical Research Unit, Saint Louis, Missouri, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Houston Methodist Hospital - Texas Medical Center, Houston, Texas, United States

and more 4 locations

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

Phase 1

Completed

Conditions: Fungal Infection

Interventions: Drug: [14C]-APX001 Oral Solution
Drug: [14C]-APX001 Solution for Infusion

First Posted Date: 2021-03-18

Last Posted Date: 2024-05-17

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 10

Registration Number: NCT04804059

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Phase 1

Terminated

Conditions: Gastric Adenocarcinoma

Interventions: Drug: Derazantinib
Drug: Derazantinib-paclitaxel-ramucirumab combination

First Posted Date: 2020-10-27

Last Posted Date: 2024-04-04

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 47

Registration Number: NCT04604132

Locations: 🇷🇺
Tomsk Research Instutite of Oncology, Tomsk, Russian Federation
🇪🇸
MD Anderson Cancer Centre, Madrid, Spain
🇧🇷
Liga Norte-Rio-Grandense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil

and more 78 locations

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

Phase 2

Terminated

Conditions: Invasive Fungal Infections

Interventions: Drug: fosmanogepix

First Posted Date: 2020-01-27

Last Posted Date: 2024-06-03

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 21

Registration Number: NCT04240886

Locations: 🇧🇪
CHU UCL Namur - Mont- Godinne University Hospital - Intensive Care Unit, Yvoir, Belgium
🇧🇪
Cliniques Universitaires de Bruxelles Hôpital Erasme - Department of Infectious Diseases, Brussels, Belgium
🇩🇪
Klinikum Neuperlach, Klinik fur Hamatologie und Onkologie, Munchen, Bavaria, Germany

and more 11 locations

A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001

Phase 1

Completed

Conditions: Fungal Infection

Interventions: Drug: APX001
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2019-11-18

Last Posted Date: 2024-05-17

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 36

Registration Number: NCT04166669

Locations: 🇳🇱
PRA-EDS, Groningen, Netherlands
🇳🇱
PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, Netherlands

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris

Phase 2

Completed

Conditions: Candidemia
Invasive Candidiases
Candida Infection

Interventions: Drug: APX001

First Posted Date: 2019-11-01

Last Posted Date: 2024-06-03

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 9

Registration Number: NCT04148287

Locations: 🇿🇦
Netcare Union Hospital Trauma Surgeons, Alberton, Gauteng, South Africa
🇿🇦
Milpark Academic Trauma Centre, Johannesburg, Gauteng, South Africa

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy